Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 17 dec 2007 - 08:51

Statutaire naam Crucell N.V.

Titel Crucell Announces Research License Agreement with ProFibrix on STAR® Technology

Bericht Leiden, The Netherlands, 17 December 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with ProFibrix BV. The license with The Netherlands based ProFibrix covers the production of specific forms of human fibrinogen, a protein involved in haemostasis (blood clotting) and tissue repair. Financial details of the agreement were not disclosed.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

200712170000000010_ProFibrix_FINAL.pdf (opens in a new window)

Datum laatste update: 22 februari 2026